-
I. FDA approval of epoprostenol for use in patients with severe PAH/scleroderma spectrum of disease. -
II. Discontinuation of patient from the study due to one of the following reasons:
-
Infusion was discontinued for more than 30 days -
Patient received a lung or heart-lung transplant -
Patient withdrew consent to participate in the study -
Patient received commercially available epoprostenol -
Patient was lost to followup -
The patient died
|